You are here


The Slim Initiative in Genomic Medicine for the Americas (SIGMA) T2D Consortium is a key initiative for the Broad's diabetes research efforts. Type 2 diabetes (T2D) is one of the most common diseases in Mexico, where its incidence is higher than the global rate. The SIGMA T2D project aims to systematically identify the genetic risk factors that contribute to this disparity, and to translate those findings into improved methods of diabetes treatment and prevention.

Working hand in hand with our colleagues in Mexico, we are carrying out genetic studies of T2D and T2D-related metabolic traits to discover causal mutations in Mexican populations, mechanistic studies to validate genetic targets for therapeutic intervention, small molecule screening to identify novel lead compounds for tool use and therapeutic development, and clinical investigations to determine the impact of genetic variation on human physiology and pharmacological response.